Fluprostenol serinol amide

(2E,4R)-5-[1,1'-联苯]-4-基-4-[[叔丁氧羰基]氨基]-2-甲基-2-戊烯酸;(R,E)-5-([1,1'-联苯]-4-基)-4-((叔丁氧羰基)氨基)-2-甲基-2-戊烯酸;(R,E)-5-([1,1’-联苯]-4-基)-4-((叔丁氧羰基)氨基)-2-甲基-2-戊烯酸;(R,E)-5-([1,1-联苯]-4-基)-4-((叔丁氧羰基)氨基)-2-甲基-2-戊烯酸;(R,E)-5-([1,1'-联苯]-4-基)-4-[(叔丁氧羰基)氨基]-2-甲基-2-戊烯酸;5-溴-2-（三氟甲基）-4-吡啶羧酸甲酯;LCZ696中间体;LCZ696中间体 7;(2E,4S)-5-(联苯-4-基)-4-[(叔丁氧基羰基)氨基]-2-甲基-2-戊烯酸;沙库巴曲缬沙坦杂质30;LCZ696中间体II;LCZ-696中间体二;(R)-5-([1,1'-联苯]-4-基)-4-((叔丁氧羰基)氨基)-2-甲基-2-戊烯酸;(R,E)-5-([1,1'-联苯]-4-基)-4-((叔丁氧羰基)氨基)-2-甲基-2-戊烯酸 LCZ696中间体II

Fluprostenol serinol amide

(R)-5-biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methyl-pent-(E)-2-enoic acid;(R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid;LCZ696（valsartan + sacubitril） impurity 30;5-Biphenyl-4-yl-4-tert-butoxycarbonylamino-2-methyl-pent-2-enoic acid;(2E,4R)-5-[1,1'-biphenyl]-4-yl-4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-2-Pentenoic acid;2-Pentenoic acid, 5-[1,1'-biphenyl]-4-yl-4-[[(1,1-dimethylethoxy)carbonyl]amino]-2-methyl-, (2E,4R)-;JXTNUXJSXXIIFE-VISDOYDDSA-N;AMBZ0394;BCP13349;AM85443;(2E,4R)-4-{[(tert-butoxy)carbonyl]amino}-2-methyl-5-(4-phenylphenyl)pent-2-enoic acid;(2E,4R)-5-(4-Biphenylyl)-4-(tert-butoxycarbonylamino)-2-methyl-2-pentenoic acid;(E)-(R)-5-biphenyl-

1176658-85-7

C₂₃H₂₇NO₄

381.46